Illumina Q4 preliminary revenue rises 5%, beats analyst expectations

Reuters01-13

<a href="https://laohu8.com/S/ILMN">Illumina</a> Q4 preliminary revenue rises 5%, beats analyst expectations

Overview

Genomics leader's preliminary Q4 revenue rises 5%, beating analyst expectations
Preliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30
Fiscal year 2025 preliminary revenue remains flat compared to 2024

Outlook

Company did not provide specific guidance for future quarters or fiscal year

Result Drivers

EX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4
FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$1.16 bln	$1.10 bln (16 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Illumina Inc is $130.00, about 10.7% below its January 12 closing price of $145.55
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nPn5NxZ72a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603680840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603680840","market":"nz","top_or_hot":-1,"title":"Illumina Q4 preliminary revenue rises 5%, beats analyst expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Q4 preliminary revenue rises 5%, beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Genomics leader's preliminary Q4 revenue rises 5%, beating analyst expectations</p></li><li><p>Preliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30</p></li><li><p>Fiscal year 2025 preliminary revenue remains flat compared to 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future quarters or fiscal year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4</p></li><li><p>FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$1.16 bln</p></td><td><p>$1.10 bln (16 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 9 \"hold\" and 3 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a> is $130.00, about 10.7% below its January 12 closing price of $145.55</p></li><li><p>The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago</p></li></ul><p>Press Release: <span>ID:nPn5NxZ72a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Q4 preliminary revenue rises 5%, beats analyst expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Q4 preliminary revenue rises 5%, beats analyst expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 22:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Q4 preliminary revenue rises 5%, beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Genomics leader's preliminary Q4 revenue rises 5%, beating analyst expectations</p></li><li><p>Preliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30</p></li><li><p>Fiscal year 2025 preliminary revenue remains flat compared to 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future quarters or fiscal year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4</p></li><li><p>FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$1.16 bln</p></td><td><p>$1.10 bln (16 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 9 \"hold\" and 3 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a> is $130.00, about 10.7% below its January 12 closing price of $145.55</p></li><li><p>The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago</p></li></ul><p>Press Release: <span>ID:nPn5NxZ72a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL1N3YE0KK:1","article_id":"2603680840","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603680840","pubTimestamp":1768313534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Illumina Q4 preliminaryrevenue rises 5%, beats analyst expectationsOverviewGenomics leader's preliminary Q4 revenue rises 5%, beating analyst expectationsPreliminary non-GAAP diluted EPS for Q4 ranges","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","ILMN":"Illumina","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务"},"translate_title":"Illumina第四季度初步营收增长5%，超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":0.9},"content_text":"Illumina Q4 preliminary revenue rises 5%, beats analyst expectationsOverviewGenomics leader's preliminary Q4 revenue rises 5%, beating analyst expectationsPreliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30Fiscal year 2025 preliminary revenue remains flat compared to 2024OutlookCompany did not provide specific guidance for future quarters or fiscal yearResult DriversEX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$1.16 bln$1.10 bln (16 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 9 \"hold\" and 3 \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Illumina Inc is $130.00, about 10.7% below its January 12 closing price of $145.55The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months agoPress Release: ID:nPn5NxZ72aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603680840","isCrawlerRequest":true}